Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:DAWN NASDAQ:HCM NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.98+1.4%$14.32$8.38▼$20.76$2.23B2.161.93 million shs1.12 million shsDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsHCMHUTCHMED$13.39+0.6%$14.45$12.82▼$19.50$2.33B0.3135,654 shs3,372 shsZVRAZevra Therapeutics$10.92+3.0%$9.63$7.16▼$13.16$648.72M0.881.00 million shs430,236 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-3.43%-1.85%-6.95%-20.35%+37.39%DAWNDay One Biopharmaceuticals0.00%0.00%+0.37%+100.47%+187.83%HCMHUTCHMED0.00%-2.13%-13.75%-10.01%-12.04%ZVRAZevra Therapeutics+5.36%+7.17%+12.87%+18.68%+32.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.98+1.4%$14.32$8.38▼$20.76$2.23B2.161.93 million shs1.12 million shsDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsHCMHUTCHMED$13.39+0.6%$14.45$12.82▼$19.50$2.33B0.3135,654 shs3,372 shsZVRAZevra Therapeutics$10.92+3.0%$9.63$7.16▼$13.16$648.72M0.881.00 million shs430,236 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-3.43%-1.85%-6.95%-20.35%+37.39%DAWNDay One Biopharmaceuticals0.00%0.00%+0.37%+100.47%+187.83%HCMHUTCHMED0.00%-2.13%-13.75%-10.01%-12.04%ZVRAZevra Therapeutics+5.36%+7.17%+12.87%+18.68%+32.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.63Moderate Buy$19.4339.02% UpsideDAWNDay One Biopharmaceuticals 2.00Hold$23.298.15% UpsideHCMHUTCHMED 2.33Hold$16.8826.07% UpsideZVRAZevra Therapeutics 2.78Moderate Buy$23.00110.55% UpsideCurrent Analyst Ratings BreakdownLatest ZVRA, HCM, ADPT, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026ADPTAdaptive Biotechnologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/6/2026ADPTAdaptive Biotechnologies BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.005/1/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/20/2026ADPTAdaptive Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/16/2026ZVRAZevra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$23.003/11/2026DAWNDay One Biopharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$27.00 ➝ $21.503/10/2026ZVRAZevra Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C+)3/10/2026ZVRAZevra Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$23.003/10/2026DAWNDay One Biopharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$22.00 ➝ $21.503/10/2026HCMHUTCHMED Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $20.003/9/2026DAWNDay One Biopharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$30.00 ➝ $21.50(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$276.98M8.06N/AN/A$1.47 per share9.51DAWNDay One Biopharmaceuticals$158.18M14.06N/AN/A$4.30 per share5.01HCMHUTCHMED$548.51M4.26$2.73 per share4.91$7.17 per share1.87ZVRAZevra Therapeutics$106.47M6.07$1.03 per share10.62$2.75 per share3.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.40N/AN/AN/A-21.48%-46.68%-18.55%N/ADAWNDay One Biopharmaceuticals-$107.32M-$1.03N/A2,153.00N/A-67.85%-23.43%-20.69%N/AHCMHUTCHMED$456.91MN/AN/A14.39N/AN/AN/AN/AN/AZVRAZevra Therapeutics$83.23M$1.338.258.40N/A78.17%57.42%26.03%5/6/2026 (Estimated)Latest ZVRA, HCM, ADPT, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026ZVRAZevra Therapeutics$0.06N/AN/AN/A$31.96 millionN/A5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million3/6/2026H2 2025HCMHUTCHMED$2.50$0.0060-$2.4940N/A$290.50 million$135.42 million2/24/2026Q4 2025DAWNDay One Biopharmaceuticals-$0.17-$0.21-$0.04-$0.2060$49.81 million$53.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.343.23DAWNDay One BiopharmaceuticalsN/A8.027.91HCMHUTCHMED0.054.964.83ZVRAZevra Therapeutics0.405.685.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%DAWNDay One Biopharmaceuticals87.95%HCMHUTCHMED8.82%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%DAWNDay One Biopharmaceuticals6.20%HCMHUTCHMED3.60%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790159.76 million150.66 millionOptionableDAWNDay One Biopharmaceuticals60103.33 million96.93 millionOptionableHCMHUTCHMED1,796174.43 million168.15 millionNot OptionableZVRAZevra Therapeutics2059.12 million57.70 millionOptionableZVRA, HCM, ADPT, and DAWN HeadlinesRecent News About These CompaniesZevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comZevra Therapeutics Announces Details for Q1 2026 Financial Results CallApril 23, 2026 | markets.businessinsider.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 16, 2026 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Stock Rating Upgraded by Wall Street ZenApril 11, 2026 | marketbeat.comStratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRAApril 7, 2026 | marketbeat.comZevra Ties NPC Testing Push To Valuation Gap And New CFOMarch 22, 2026 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Moderate Buy†by AnalystsMarch 22, 2026 | defenseworld.netDZevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)March 20, 2026 | globenewswire.comBTIG initiates coverage of Zevra Therapeutics (ZVRA) with buy recommendationMarch 16, 2026 | msn.comZevra shares jump after selling SDX portfolio for $50MMarch 16, 2026 | msn.comZevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 MillionMarch 16, 2026 | globenewswire.comCan Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge?March 13, 2026 | uk.finance.yahoo.comZevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Driven by ...March 11, 2026 | finance.yahoo.comIs Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price PerformanceMarch 11, 2026 | finance.yahoo.comGeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type CMarch 10, 2026 | finance.yahoo.comZevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial ModelMarch 10, 2026 | seekingalpha.comZevra Therapeutics, Inc. (ZVRA) Q4 FY2025 earnings call transcriptMarch 10, 2026 | finance.yahoo.comZevra Therapeutics: Zevra Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 10, 2026 | finanznachrichten.deZVRA stock soars on upbeat Q4 results, optimism for EMA approval of Niemann-Pick disease treatmentMarch 10, 2026 | msn.comZevra Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 9, 2026 | markets.businessinsider.comZevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call TranscriptMarch 9, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZVRA, HCM, ADPT, and DAWN Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$14.04 +0.26 (+1.88%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Day One Biopharmaceuticals NASDAQ:DAWNDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.HUTCHMED NASDAQ:HCM$13.38 +0.09 (+0.64%) As of 11:17 AM Eastern This is a fair market value price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Zevra Therapeutics NASDAQ:ZVRA$10.92 +0.32 (+2.97%) As of 11:17 AM Eastern This is a fair market value price provided by Massive. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
